申请人:Elan Pharmaceuticals, Inc.
公开号:US06518424B1
公开(公告)日:2003-02-11
Substituted pyrimidines that have the general structure:
in which the symbol R1 represents a C1-C6 alkyl, C1-C6 alkoxy or halogen atom; R2 represents a phenyl group, substituted phenyl group, benzyl moiety, substituted benzyl moiety, C3-C7 cycloalkyl, or substituted C3-C7 cycloalkyl; R3 represents a hydrogen or C1-C6 alkyl group, R4 represents —H, —OH, —N3 or —NHCOCH3; and R5 represents H are provided. These compounds have activity as inhibitors of phospholipase A2, and are useful in treating disorders mediated by phospholipase A2.
提供一种具有一般结构的取代嘧啶化合物:其中符号R1代表C1-C6烷基、C1-C6烷氧基或卤原子;R2代表苯基、取代苯基、苄基、取代苄基、C3-C7环烷基或取代C3-C7环烷基;R3代表氢或C1-C6烷基,R4代表-H、-OH、-N3或-NHCOCH3;R5代表H。这些化合物具有作为磷脂酶A2抑制剂的活性,并且在治疗由磷脂酶A2介导的疾病中有用。